Veracyte Inc
NASDAQ:VCYT
Veracyte Inc
Revenue
Veracyte Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Veracyte Inc
NASDAQ:VCYT
|
Revenue
$361.1m
|
CAGR 3-Years
45%
|
CAGR 5-Years
31%
|
CAGR 10-Years
32%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Veracyte Inc
Revenue Breakdown
Breakdown by Geography
Veracyte Inc
Total Revenue:
361.1m
USD
|
United States:
334.5m
USD
|
International:
26.5m
USD
|
Breakdown by Segments
Veracyte Inc
Total Revenue:
361.1m
USD
|
Testing Revenue:
326.5m
USD
|
Biopharmaceutical And Other Revenue:
18.9m
USD
|
Product Revenue:
15.6m
USD
|
Other Testing Revenue:
7.8m
USD
|
See Also
What is Veracyte Inc's Revenue?
Revenue
361.1m
USD
Based on the financial report for Dec 31, 2023, Veracyte Inc's Revenue amounts to 361.1m USD.
What is Veracyte Inc's Revenue growth rate?
Revenue CAGR 10Y
32%
Over the last year, the Revenue growth was 22%. The average annual Revenue growth rates for Veracyte Inc have been 45% over the past three years , 31% over the past five years , and 32% over the past ten years .